Reference
1. Azim A, Green B, Lau L, Rupani H, Jayasekera N, Bruce K, Howarth P.
Peripheral airways type 2 inflammation, neutrophilia and microbial
dysbiosis in severe asthma. Allergy 2021, Jan 7(doi:
10.1111/all.14732.).
2. Ward C, Gardiner PV, Booth H, Walters EH. Intrasubject variability in
airway inflammation sampled by bronchoalveolar lavage in stable
asthmatics. Eur Respir J 1995: 8(11): 1866-1871.
3. Aleman F, Lim HF, Nair P. Eosinophilic Endotype of Asthma.Immunology and Allergy Clinics of North America 2016: 36(3):
559-568.
4. Chu DK, Al-Garawi A, Llop-Guevara A, Pillai RA, Radford K, Shen P,
Walker TD, Goncharova S, Calhoun WJ, Nair P, Jordana M. Therapeutic
potential of anti-IL-6 therapies for granulocytic airway inflammation in
asthma. Allergy, Asthma & Clinical Immunology 2015: 11(1): 1-6.
5. Cox C, Kjarsgaard M, Surette M, Cox P, Nair P. A multidimensional
approach to the management of severe asthma: Inflammometry, molecular
microbiology and bronchial thermoplasty. Canadian Respiratory
Journal 2015: 22(4): 221 - 224.
6. Sze E, Bhalla A, Nair P. Mechanisms and therapeutic strategies for
non-T2 asthma. Allergy 2020: 75(2): 311-325.
7. Impellizzieri D, Ridder F, Raeber ME, Egholm C, Woytschak J, Kolios
AGA, Legler DF, Boyman O. IL-4 receptor engagement in human neutrophils
impairs their migration and extracellular trap formation. J
Allergy Clin Immunol 2019: 144(1): 267-279.e264.
8. Hadjigol S, Netto KG, Maltby S, Tay HL, Nguyen TH, Hansbro NG, Eyers
F, Hansbro PM, Yang M, Foster PS. Lipopolysaccharide induces
steroid-resistant exacerbations in a mouse model of allergic airway
disease collectively through IL-13 and pulmonary macrophage activation.Clin Exp Allergy 2020: 50(1): 82-94.
9. Mukherjee M, Nair P. Autoimmune Responses in Severe Asthma.Allergy Asthma Immunol Res 2018: 10.
10. Nair P, O’Byrne PM. The interleukin-13 paradox in asthma: effective
biology, ineffective biologicals. Eur Respir J 2019: 53(2).